Prostaglandin E2: From clinical applications to its potential role in bone-muscle crosstalk and myogenic differentiation

Chenglin Mo, Sandra Romero-Suarez, Lynda Bonewald, Mark Johnson, Marco Brotto

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Prostaglandin E2 (PGE2), a prostanoid synthesized from arachidonic acid via the cyclooxygenase pathway, is a modulator of physiological responses including inflammation, fever, and muscle regeneration. Several patents have been filed that are related to PGE2, one of them being directly related to skeletal muscles. In this report, we first summarize the key patents describing inventions for the utilization of PGE2for either diagnostic or therapeutic purposes, including skeletal muscle. In the second part of our work we present new and exciting data that demonstrates that PGE2accelerates skeletal muscle myogenic differentiation. Our discovery resulted from our recent and novel concept of bone-muscle crosstalk. Bone and muscle are anatomically intimate endocrine organs and we aimed to determine whether this anatomical intimacy also translates into a biochemical communication from bone cells to muscle cells at the in vitro level. The effects of MLOY4 osteocyte-like cell conditioned medium (CM) and three osteocyte-secreted factors, PGE2, sclerostin and monocyte chemotactic protein (MCP-3), on C2C12 myogenic differentiation were evaluated using morphological analyses, a customized 96-gene PCR array, and measurements of intracellular calcium levels. MLO-Y4 CM and PGE2, but not sclerostin and MCP-3, induced acceleration of myogenesis of C2C12 myoblasts that was linked with significant modifications in intracellular calcium homeostasis. This finding should further stimulate the pursuit of new patents to explore the use of PGE2and the new concept of bone-muscle crosstalk for the development and application of inventions designed to treat muscle diseases characterized by enhanced muscle wasting, such as sarcopenia.

Original languageEnglish (US)
Pages (from-to)223-229
Number of pages7
JournalRecent Patents on Biotechnology
Volume6
Issue number3
DOIs
StatePublished - 2012
Externally publishedYes

Fingerprint

Crosstalk
Dinoprostone
Muscle
Bone
Patents
Bone and Bones
Muscles
Osteocytes
Skeletal Muscle
Muscle Development
Conditioned Culture Medium
Chemokine CCL7
Sarcopenia
Calcium
Myoblasts
Patents and inventions
Prostaglandin-Endoperoxide Synthases
Cell Communication
Muscle Cells
Prostaglandins

Keywords

  • Bone cells
  • Bone secreted factors
  • Bone-muscle crosstalk
  • Calcium release
  • Calcium-induced calcium release (CICR)
  • EP Receptors
  • Excitation-contraction coupling
  • Gene expression
  • Inventions
  • MLO-Y4 conditioned media
  • MLO-Y4 osteocytes-like cells
  • Muscle regulatory factors
  • Muscle secreted factors
  • MyoD
  • Myogenic acceleration
  • Myokines
  • Osteocytes
  • Patents
  • PGE
  • Prostaglandins
  • Prostanoid

ASJC Scopus subject areas

  • Biotechnology
  • Applied Microbiology and Biotechnology
  • Bioengineering

Cite this

Prostaglandin E2 : From clinical applications to its potential role in bone-muscle crosstalk and myogenic differentiation. / Mo, Chenglin; Romero-Suarez, Sandra; Bonewald, Lynda; Johnson, Mark; Brotto, Marco.

In: Recent Patents on Biotechnology, Vol. 6, No. 3, 2012, p. 223-229.

Research output: Contribution to journalArticle

Mo, Chenglin ; Romero-Suarez, Sandra ; Bonewald, Lynda ; Johnson, Mark ; Brotto, Marco. / Prostaglandin E2 : From clinical applications to its potential role in bone-muscle crosstalk and myogenic differentiation. In: Recent Patents on Biotechnology. 2012 ; Vol. 6, No. 3. pp. 223-229.
@article{32c0896367494c5a8e748f3a00584587,
title = "Prostaglandin E2: From clinical applications to its potential role in bone-muscle crosstalk and myogenic differentiation",
abstract = "Prostaglandin E2 (PGE2), a prostanoid synthesized from arachidonic acid via the cyclooxygenase pathway, is a modulator of physiological responses including inflammation, fever, and muscle regeneration. Several patents have been filed that are related to PGE2, one of them being directly related to skeletal muscles. In this report, we first summarize the key patents describing inventions for the utilization of PGE2for either diagnostic or therapeutic purposes, including skeletal muscle. In the second part of our work we present new and exciting data that demonstrates that PGE2accelerates skeletal muscle myogenic differentiation. Our discovery resulted from our recent and novel concept of bone-muscle crosstalk. Bone and muscle are anatomically intimate endocrine organs and we aimed to determine whether this anatomical intimacy also translates into a biochemical communication from bone cells to muscle cells at the in vitro level. The effects of MLOY4 osteocyte-like cell conditioned medium (CM) and three osteocyte-secreted factors, PGE2, sclerostin and monocyte chemotactic protein (MCP-3), on C2C12 myogenic differentiation were evaluated using morphological analyses, a customized 96-gene PCR array, and measurements of intracellular calcium levels. MLO-Y4 CM and PGE2, but not sclerostin and MCP-3, induced acceleration of myogenesis of C2C12 myoblasts that was linked with significant modifications in intracellular calcium homeostasis. This finding should further stimulate the pursuit of new patents to explore the use of PGE2and the new concept of bone-muscle crosstalk for the development and application of inventions designed to treat muscle diseases characterized by enhanced muscle wasting, such as sarcopenia.",
keywords = "Bone cells, Bone secreted factors, Bone-muscle crosstalk, Calcium release, Calcium-induced calcium release (CICR), EP Receptors, Excitation-contraction coupling, Gene expression, Inventions, MLO-Y4 conditioned media, MLO-Y4 osteocytes-like cells, Muscle regulatory factors, Muscle secreted factors, MyoD, Myogenic acceleration, Myokines, Osteocytes, Patents, PGE, Prostaglandins, Prostanoid",
author = "Chenglin Mo and Sandra Romero-Suarez and Lynda Bonewald and Mark Johnson and Marco Brotto",
year = "2012",
doi = "10.2174/1872208311206030223",
language = "English (US)",
volume = "6",
pages = "223--229",
journal = "Recent Patents on Biotechnology",
issn = "1872-2083",
publisher = "Bentham Science Publishers B.V.",
number = "3",

}

TY - JOUR

T1 - Prostaglandin E2

T2 - From clinical applications to its potential role in bone-muscle crosstalk and myogenic differentiation

AU - Mo, Chenglin

AU - Romero-Suarez, Sandra

AU - Bonewald, Lynda

AU - Johnson, Mark

AU - Brotto, Marco

PY - 2012

Y1 - 2012

N2 - Prostaglandin E2 (PGE2), a prostanoid synthesized from arachidonic acid via the cyclooxygenase pathway, is a modulator of physiological responses including inflammation, fever, and muscle regeneration. Several patents have been filed that are related to PGE2, one of them being directly related to skeletal muscles. In this report, we first summarize the key patents describing inventions for the utilization of PGE2for either diagnostic or therapeutic purposes, including skeletal muscle. In the second part of our work we present new and exciting data that demonstrates that PGE2accelerates skeletal muscle myogenic differentiation. Our discovery resulted from our recent and novel concept of bone-muscle crosstalk. Bone and muscle are anatomically intimate endocrine organs and we aimed to determine whether this anatomical intimacy also translates into a biochemical communication from bone cells to muscle cells at the in vitro level. The effects of MLOY4 osteocyte-like cell conditioned medium (CM) and three osteocyte-secreted factors, PGE2, sclerostin and monocyte chemotactic protein (MCP-3), on C2C12 myogenic differentiation were evaluated using morphological analyses, a customized 96-gene PCR array, and measurements of intracellular calcium levels. MLO-Y4 CM and PGE2, but not sclerostin and MCP-3, induced acceleration of myogenesis of C2C12 myoblasts that was linked with significant modifications in intracellular calcium homeostasis. This finding should further stimulate the pursuit of new patents to explore the use of PGE2and the new concept of bone-muscle crosstalk for the development and application of inventions designed to treat muscle diseases characterized by enhanced muscle wasting, such as sarcopenia.

AB - Prostaglandin E2 (PGE2), a prostanoid synthesized from arachidonic acid via the cyclooxygenase pathway, is a modulator of physiological responses including inflammation, fever, and muscle regeneration. Several patents have been filed that are related to PGE2, one of them being directly related to skeletal muscles. In this report, we first summarize the key patents describing inventions for the utilization of PGE2for either diagnostic or therapeutic purposes, including skeletal muscle. In the second part of our work we present new and exciting data that demonstrates that PGE2accelerates skeletal muscle myogenic differentiation. Our discovery resulted from our recent and novel concept of bone-muscle crosstalk. Bone and muscle are anatomically intimate endocrine organs and we aimed to determine whether this anatomical intimacy also translates into a biochemical communication from bone cells to muscle cells at the in vitro level. The effects of MLOY4 osteocyte-like cell conditioned medium (CM) and three osteocyte-secreted factors, PGE2, sclerostin and monocyte chemotactic protein (MCP-3), on C2C12 myogenic differentiation were evaluated using morphological analyses, a customized 96-gene PCR array, and measurements of intracellular calcium levels. MLO-Y4 CM and PGE2, but not sclerostin and MCP-3, induced acceleration of myogenesis of C2C12 myoblasts that was linked with significant modifications in intracellular calcium homeostasis. This finding should further stimulate the pursuit of new patents to explore the use of PGE2and the new concept of bone-muscle crosstalk for the development and application of inventions designed to treat muscle diseases characterized by enhanced muscle wasting, such as sarcopenia.

KW - Bone cells

KW - Bone secreted factors

KW - Bone-muscle crosstalk

KW - Calcium release

KW - Calcium-induced calcium release (CICR)

KW - EP Receptors

KW - Excitation-contraction coupling

KW - Gene expression

KW - Inventions

KW - MLO-Y4 conditioned media

KW - MLO-Y4 osteocytes-like cells

KW - Muscle regulatory factors

KW - Muscle secreted factors

KW - MyoD

KW - Myogenic acceleration

KW - Myokines

KW - Osteocytes

KW - Patents

KW - PGE

KW - Prostaglandins

KW - Prostanoid

UR - http://www.scopus.com/inward/record.url?scp=84872505931&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872505931&partnerID=8YFLogxK

U2 - 10.2174/1872208311206030223

DO - 10.2174/1872208311206030223

M3 - Article

C2 - 23092433

AN - SCOPUS:84872505931

VL - 6

SP - 223

EP - 229

JO - Recent Patents on Biotechnology

JF - Recent Patents on Biotechnology

SN - 1872-2083

IS - 3

ER -